Q3 Earnings Forecast for TEVA Issued By HC Wainwright

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) – Analysts at HC Wainwright issued their Q3 2026 EPS estimates for Teva Pharmaceutical Industries in a research report issued to clients and investors on Monday, November 2nd. HC Wainwright analyst D. Tsao anticipates that the company will post earnings of $0.71 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $52.00 price objective on the stock. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.00 per share. HC Wainwright also issued estimates for Teva Pharmaceutical Industries’ Q4 2026 earnings at $0.75 EPS, FY2026 earnings at $1.94 EPS, Q1 2027 earnings at $0.62 EPS, Q2 2027 earnings at $0.72 EPS, Q3 2027 earnings at $0.82 EPS, Q4 2027 earnings at $0.87 EPS and FY2027 earnings at $3.03 EPS.

A number of other analysts also recently issued reports on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the company an “overweight” rating in a report on Monday, October 12th. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. TD Cowen upped their target price on Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the stock a “buy” rating in a report on Wednesday. Leerink Partners started coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, September 9th. They set an “outperform” rating and a $45.00 price target for the company. Finally, UBS Group lifted their target price on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a report on Friday, September 4th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus price target of $46.69.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $41.83 on Thursday. Teva Pharmaceutical Industries has a 1-year low of $22.70 and a 1-year high of $43.34. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 1.56. The stock has a market cap of $48.74 billion, a P/E ratio of 97.27, a PEG ratio of 3.89 and a beta of 0.97. The stock has a 50 day simple moving average of $39.32 and a 200 day simple moving average of $34.68.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.14. The company had revenue of $4.39 billion during the quarter, compared to analysts’ expectations of $4.23 billion. Teva Pharmaceutical Industries had a net margin of 2.94% and a return on equity of 33.22%. Teva Pharmaceutical Industries’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.78 EPS.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Hedge funds have recently added to or reduced their stakes in the company. Parallel Advisors LLC increased its holdings in shares of Teva Pharmaceutical Industries by 8.7% during the third quarter. Parallel Advisors LLC now owns 4,626 shares of the company’s stock valued at $183,000 after acquiring an additional 370 shares in the last quarter. Sage Rhino Capital LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 5.6% in the 1st quarter. Sage Rhino Capital LLC now owns 7,874 shares of the company’s stock worth $237,000 after purchasing an additional 417 shares in the last quarter. Envestnet Portfolio Solutions Inc. lifted its holdings in shares of Teva Pharmaceutical Industries by 7.1% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 7,311 shares of the company’s stock worth $248,000 after purchasing an additional 483 shares in the last quarter. First Trust Advisors LP grew its position in Teva Pharmaceutical Industries by 5.9% in the 1st quarter. First Trust Advisors LP now owns 9,619 shares of the company’s stock valued at $290,000 after purchasing an additional 539 shares during the period. Finally, EverSource Wealth Advisors LLC grew its position in Teva Pharmaceutical Industries by 64.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,658 shares of the company’s stock valued at $50,000 after purchasing an additional 647 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Brian Savage sold 7,342 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, September 18th. The shares were sold at an average price of $38.85, for a total value of $285,236.70. Following the completion of the sale, the insider directly owned 8,500 shares of the company’s stock, valued at approximately $330,225. The trade was a 46.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Roberto Mignone sold 367,600 shares of the business’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $39.06, for a total value of $14,358,456.00. The disclosure for this sale is available in the SEC filing. Insiders own 0.54% of the company’s stock.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Earnings and guidance beat expectations: Third-quarter adjusted earnings were $0.86 per share versus $0.72 expected, and revenue of about $4.39 billion topped the $4.23 billion consensus. Teva raised its 2026 revenue and product-sales outlook, citing growth in branded medicines. Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up
• Positive Sentiment: UZEDY sales surged: The long-acting schizophrenia treatment generated $85 million in U.S. third-quarter sales, up 96% year over year. Teva lifted its 2026 UZEDY revenue forecast to $290 million–$310 million from $270 million–$290 million. UZEDY Q3 U.S. Net Sales Reach $85M
• Positive Sentiment: Analyst endorsement: TD Cowen raised its price target from $55 to $57 and maintained a Buy rating, signaling confidence in further potential upside. TD Cowen price-target update
• Positive Sentiment: Biosimilar portfolio expansion: Teva secured U.S. commercialization rights to two Samsung Bioepis immunology biosimilars, broadening its product portfolio and potential future revenue sources. Teva and Samsung Bioepis biosimilar agreement
• Negative Sentiment: Drug-development setback and sales pressure: Teva ended its Phase 2 emrusolmin study after an interim review found insufficient efficacy. Quarterly revenue also declined 1.9% year over year, and the company expects U.S. drug-pricing pressure to affect Austedo. Why Teva Is Dropping a Drug Trial While Raising Its Outlook

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company is one of the world’s largest producers of generic medicines and develops, manufactures and distributes prescription products across a broad range of therapeutic areas.

Teva’s portfolio includes generic medicines, specialty pharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products. Its specialty medicines include treatments for neurological and movement disorders, respiratory conditions, migraine and other chronic diseases.